DynPort Vaccines

Executive Summary

DynPort Vaccine Company (DVC), a subsidiary of General Dynamics Information Technology, is a specialized contractor providing full-lifecycle biopharmaceutical development services to the U.S. federal government. Founded in 1997 and headquartered in Frederick, Maryland, DVC focuses on medical countermeasures (MCMs) against emerging infectious diseases and bioterror threats, managing programs from nonclinical studies through FDA licensure for agencies like the Department of Defense. With a stable government-funder model and a track record in advancing vaccines for anthrax, smallpox, and plague, DVC operates as a low-risk, mission-critical partner in national health security. The company's private status and reliance on government contracts limit upside but provide predictable revenue streams. Key upcoming catalysts include new contract awards from BARDA or DoD, progress on existing MCM programs toward FDA milestones, and potential expansions in biodefense funding that could accelerate development timelines.

Upcoming Catalysts (preview)

• Q3 2026Award of new BARDA or DoD MCM development contract70% success
• Q4 2026FDA clearance for a Phase 2 trial of a lead biodefense vaccine candidate60% success
• Q1 2027Announcement of facility expansion or strategic partnership to scale MCM production50% success